AI Terminal
Zur Rose Group AG
Regulatory Filings • Jul 15, 2025
1021_rns_2025-07-15_19b05856-e702-4815-baf8-f248cd88b6ea.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 15 July 2025 07:00
gematik extends DocMorris CardLink approval until January 2027
DocMorris AG / Key word(s): Miscellaneous
gematik extends DocMorris CardLink approval until January 2027
15.07.2025 / 07:00 CET/CEST
Frauenfeld, 15 July 2025
Press release
gematik extends DocMorris CardLink approval until January 2027
- Approval extension ensures seamless transition to successor technology PoPP
- gematik will also enable contactless use of the eGK without a PIN in the context of PoPP
gematik has extended the product approval for DocMorris’ CardLink solution until the end of January 2027. Patients can therefore continue to redeem their e-prescriptions with their electronic health card (eGK) and the DocMorris app, while at the same time a seamless transition to the successor technology PoPP (Proof of Patient Presence) is ensured.
“We welcome the fact that gematik worked with all parties involved at an early stage to find a transitional arrangement for fully digital e-prescription redemption until the nationwide introduction of PoPP. By enabling the contactless use of the eGK without a PIN, even in the context of PoPP, our customers can continue to rely on learned redemption methods for their e-prescriptions in the future,” says Walter Hess, CEO DocMorris.
Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: [email protected], phone: +41 52 560 58 10
Media contact
Torben Bonnke, Director Communications
Email: [email protected], phone: +49 171 864 888 1
Agenda
| 19 August 2025 | 2025 Half-year results (conference call/webcast) |
| 16 October 2025 | Q3/2025 Trading update |
| 20 January 2026 | Sales 2025 |
| 19 March 2026 | 2025 Full-year results and outlook 2026 (conference call/webcast) |
| 16 April 2026 | Q1/2026 Trading update |
| 12 May 2026 | Annual General Meeting, Zurich |
| 19 August 2026 | 2026 Half-year results (conference call/webcast) |
| 15 October 2026 | Q3/2026 Trading update |
DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.
End of Media Release
| Language: | English |
| Company: | DocMorris AG |
| Walzmühlestrasse 49 | |
| 8500 Frauenfeld | |
| Switzerland | |
| ISIN: | CH0042615283 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2169628 |
| End of News | EQS News Service |
2169628 15.07.2025 CET/CEST